Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model

Fig. 3

The different expression of chemokines after hMSC treatment in the skin and lungs. a Level of mRNA for CCL1, CCL2, CCL3, CCL5 CCL8, CCL17, and CCL22 in the skin and lungs 14 and 28 days after transplantation. b mRNA expression of CCR4, CCL17, and CCL22 receptor, and CCR8 and CCL1 receptor in the lungs 14 days after transplantation. Each value indicates the mean ± SEM of 4–9 mice per group. *P < 0.05; **P < 0.01, ***P < 0.001

Back to article page